A Phase Ib/II Study to Evaluate the Safety and Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Combination With Quemliclustat in Unresectable Locally Advanced and Metastatic Urothelial Carcinoma
This phase Ib/II trial tests the safety, side effects, and best dose of quemliclustat in combination with enfortumab vedotin and pembrolizumab, and to see how well the combination works for the treatment of bladder, renal pelvis, or ureter urothelial cancer that cannot be removed by surgery (unresectable), that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of cancer cells. Enfortumab attaches to a protein called nectin-4 on cancer cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Quemliclustat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving quemliclustat in combination with enfortumab vedotin and pembrolizumab and may be safe, tolerable and/or effective in treating patients with unresectable locally advanced and metastatic urothelial cancer.
• Participants must be at least 18 years of age on the day of signing informed consent. Participant provides written informed consent for trial
• Participants must have previously untreated locally advanced or metastatic bladder cancer including bladder cancer \[stage IIIB: T1-T4N2-3M0, stage IVa: T4bAnyNM0 or AnyTAnyNM1a, and stage IVB: AnyTAnyNM1b clinical stage per American Joint Commission on Cancer (AJCC)\] or renal pelvis or ureter cancer \[stage IV: T4Nx-0M0, AnyTN1-2M0, AnyTAnyNM1 clinical stage per AJCC\]. Lymph node with ≥ 15 mm short axis or biopsy-positive for carcinoma will be considered pathologically enlarged and measurable
• Participants must have either conventional urothelial carcinoma or urothelial carcinoma variants. A review of pathology by a local expert genitourinary (GU) pathologist is required to confirm the diagnosis. Any component (%) of non-conventional urothelial noted on tumor specimen is allowed for only histologic subtypes listed below in up to 20% of participants enrolled in this study.
‣ Urothelial carcinoma with squamous differentiation
⁃ Urothelial carcinoma with glandular differentiation
⁃ Urothelial carcinoma with trophoblastic differentiation
⁃ Nested urothelial carcinoma
⁃ Tubular and microcystic urothelial carcinoma
⁃ Micropapillary urothelial carcinoma
⁃ Lymphoepithelioma-like urothelial carcinoma
⁃ Plasmacytoid urothelial carcinoma
⁃ Sarcomatoid urothelial carcinoma
⁃ Giant cell urothelial carcinoma
⁃ Lipid-rich urothelial carcinoma
⁃ Clear cell (glycogen rich) urothelial carcinoma
⁃ Poorly differentiated urothelial carcinoma
⁃ Squamous cell neoplasms including pure squamous cell carcinomas, verrucous carcinomas and squamous cell papilloma
• Measurable disease by RECIST v 1.1
• Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2
• Available baseline fresh biopsy tissue sample obtained in the protocol RG1712006 or RG1125031 though clinically indicated procedures or participants must be willing to undergo a baseline research biopsy when safe and feasible
• Participant must have an estimated life expectancy of at least 3 months
• Hemoglobin ≥ 9 g/dl
• Absolute neutrophil count: ≥ 1500/ µL
• White blood cell count: ≥ 3000/µL
• Absolute lymphocyte count: ≥ 1000/µL
• Platelet count: ≥ 100.000/µL (without transfusion support)
• Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT): ≤ 2.5 x upper limit of normal (ULN)
• Total bilirubin: ≤ 1.5 mg/dl except for patients with Gilbert's syndrome who must have a total bilirubin ≤ 3 mg/dl
• Creatinine clearance: ≥ 30 ml/min/1.73m\^2 by the method of Chronic Kidney Disease Epidemiology Collaboration (CKI-EPI) or ≥ 30 ml/min by the method of 24 hour (h) clearance of creatinine calculation
• International Normalized Ratio (INR): \< 1.5